Navigation Links
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Date:6/13/2008

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS) had been presented at the 13th Congress of the European Hematology Association (EHA) at the Bella Center in Copenhagen, Denmark. At the Congress, data were presented in a subset of 26 patients with high-risk MDS by French-American-British (FAB) Group criteria.

The median age of the patients in the subset was 71 years (range of 59-82 years). Twelve patients were diagnosed with refractory anemia with excess blasts (RAEB) and 9 patients were diagnosed with RAEB-t. Five patients were diagnosed with either chronic myelomonocytic leukemias (CMML) (3) or as unknown (2). Fifteen patients had intermediate cytogenetics and 11 had unfavorable cytogenetics. Sixteen of the patients were classified as Intermediate-2 risk by the International Prognostic Scoring System (IPSS) system (1.5-2.0), and 10 were classified as high risk (greater than or equal to 2.5).

Eight of the 26 patients had received prior treatment for their disease. Prior agents used included arsenic trioxide, thalidomide, Ara-C, imatinib mesylate, interferon, amifostine, melphalan, hydroxyurea and 5-azacitiadine.

The overall complete response rate was 38% (7 CR and 3 CRp). Three of 10 responders received prior treatment; 8 of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was 3.9 months (2.5-28.6).


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Oregon , May 28, 2015 ... "Global Syphilis Testing Market - Size, Industry Analysis, Trends, Opportunities, Growth ... to reach $3.6 billion by 2020. The secondary syphilis ... through 2020. Latin America , ... (LAMEA) market accounted for about 43% revenue ...
(Date:5/28/2015)... DIEGO , May 28, 2015  Service ... programs, today announced that Fresenius Kabi, a global ... technologies for infusion, transfusion and clinical nutrition, has ... & Performance (SCP) Standards for the seventh ... quantify service effectiveness based upon a stringent set ...
(Date:5/28/2015)... FORT WORTH, Texas , May 28, 2015 /PRNewswire/ ... defines and segments the concerned market with analysis and ... million in 2014 and is estimated to reach $1,177.8 ... 2014 to 2019. Browse through the TOC ... the industry trends and segments, with help of various ...
Breaking Medicine Technology:Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 3Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3
(Date:5/28/2015)... Workers’ compensation costs per claim in Michigan were lower ... the Workers Compensation Research Institute (WCRI) said, with ... WCRI study, CompScope™ Benchmarks for Michigan, 15th Edition, ... more of work with those of 16 other states. ... 4 percent lower than similar claims from 2008. That was ...
(Date:5/28/2015)... May 28, 2015 Baptist Medical Center ... patients suffering from acute stroke or other neurological conditions. ... one of a few in the country and the ... emergency needs such as brain aneurysms. , “Baptist ... care of patients who are impacted by stroke,” said ...
(Date:5/28/2015)... Houston, TX (PRWEB) May 28, 2015 ... respected cosmetic surgeons , has announced that the new ... Accreditation. The American Association of Accreditation of Ambulatory Surgery ... state-of-the-art surgery center . , According to Dr. ... for meeting the standards of a Class C ambulatory ...
(Date:5/28/2015)... Sexual Health Innovations, a nonprofit ... health and wellbeing in the United States, announced ... (USF) will be the first institution to adopt ... reporting system. , Callisto is designed to ... experience for college sexual assault survivors, to give ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 A bucket ... adventures. Each item on the bucket list ... events, experiences and tasks that the owner wants to ... right or wrong when it comes to making this ... business, writing poems, publishing a book, seeing the Grand ...
Breaking Medicine News(10 mins):Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 3Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3
... of expertise and other factors when ... ... CIGNA Behavioral Health,(CBH) members can now view robust, online ... including license,levels, languages spoken, educational background, areas of specialization,and years ...
... -- Researchers at Mayo Clinic in Jacksonville have discovered how ... proteins in the brain, resulting in a common dementia, ... number of age-related neurological disorders. , In the Sept. ... that absence of a gene known as progranulin leads to ...
... be on,display throughout The Kroger Co.,s (NYSE: KR ... partners with vendors and suppliers to support,National Breast Cancer ... tags can be found on shelves in Kroger,stores across ... support breast cancer awareness in their community. Several of,Kroger,s ...
... Climb to Conquer Cancer will follow four professional U.S., ... Alaska, NEW YORK, Sept. 27 Fred Hutchinson ... expedition to an unclimbed,mountain in the name of cancer ... expedition. The inaugural Climb to Conquer Cancer, performed ...
... QMed, Inc.,(Nasdaq: QMED ) today announced it ... August 31, 2007 revenue of approximately $10.8 million and,$26.6 ... $13 million,respectively. The Company,s cash position as of August ... Jane Murray, president and CEO, said, "During the ...
... Edition Strawberry Jelly Krimpets Will Benefit Online ... for Breast Cancer Support and Information, PHILADELPHIA, Sept. ... philanthropic product offering, the,Tastykake Strawberry Jelly Krimpet. 10% of ... will be donated to breastcancer.org, a,Narberth, Pennsylvania based online ...
Cached Medicine News:Health News:CIGNA Behavioral Health Offers Members Online Provider Profiles 2Health News:Loss of gene leads to protein splicing and buildup of toxic proteins in neurons 2Health News:Kroger 'Pink Tag' Campaign to Raise $2.5 Million for Breast Cancer Awareness in October 2Health News:Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 3Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 2Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 3
Inquire...
Inquire...
Inquire...
... operation and optical performance, the SZX7 is ... comfort in every task, from routine preparations ... of the best zoom ratios in its ... true color and accurate reproduction of the ...
Medicine Products: